Clinical Trial

Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this phase I clinical trial is to evaluate the safety and tolerability of intratumoral injection of mechanically reprogrammed macrophage-derived exosomes (MRMEs) in adults aged 18-65 years with advanced solid tumors who have failed, are ineligible for, or are intolerant of standard therapies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07563972
Lead Sponsor West China Hospital
Conditions Advanced Solid Tumors, Neoplasm
Enrollment 9 participants
Start Date 2026-05-10
Primary Completion 2027-03 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-11